Previous Article | Next Article 
Journal of Virology, July 1999, p. 5621-5629, Vol. 73, No. 7
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Failure To Cleave Murine Leukemia Virus Envelope Protein Does Not
Preclude Its Incorporation in Virions and Productive
Virus-Receptor Interaction
Tatiana
Zavorotinskaya and
Lorraine M.
Albritton*
Department of Microbiology and Immunology,
University of Tennessee, Memphis, Tennessee
Received 12 January 1999/Accepted 12 April 1999
 |
ABSTRACT |
It is thought that complete cleavage of retroviral envelope protein
into mature surface protein (SU) and transmembrane protein (TM) is
critical for its assembly into virions and the formation of infectious
virus particles. Here we report the identification of highly
infectious, cleavage-deficient envelope mutant proteins. Substitution
of aspartate for lysine 104, arginines 124 and 126, or arginines 223 and 225 strongly suppressed cleavage of the envelope precursor and yet
allowed efficient incorporation of precursor molecules as the
predominant species in virions that were almost as infectious as
the wild-type virus. These results indicate that cleavage of the
envelope precursor into mature SU and TM is not necessary for assembly
into virions. Moreover, they call into question how many mature
envelope protein subunits are required to complete virus entry,
suggesting that a very few molecules suffice. The failure of host cell
proteases to cleave these mutant proteins, whose substitutions are
distal to the actual site of cleavage, suggests that the envelope
precursor is misfolded, sequestering the cleavage site. In agreement
with this, all cleavage mutant proteins exhibited significant
losses of receptor binding, suggesting that these residues play roles
in proper envelope protein folding. We also identified a charged
residue, arginine 102, whose substitution suppressed envelope cleavage
and allowed precursor incorporation but resulted in virions that were
virtually noninfectious and that exhibited the greatest reduction in
receptor binding. Placement of these cleavage mutations into envelope
proteins of targeted retroviral vectors for human gene therapy may
prevent loss of the modified surface proteins from virions, improving
their infectivity and storage hardiness.
 |
INTRODUCTION |
Ecotropic murine leukemia viruses
(MLV) are simple type C retroviruses carrying three genes,
gag, pol, and env. The first and last
genes encode the structural proteins for the assembly of infectious
progeny virus. The protein products of the gag gene make up
the core of the virus particle, while the env gene encodes the envelope proteins found in the virus membrane. Synthesized as a
polyprotein, the envelope proteins are targeted for translation in
the endoplasmic reticulum via a cleaved amino-terminal signal peptide.
Following glycosylation in the endoplasmic reticulum, the precursor
molecules form trimers. A second internal cleavage by an unidentified
host cell protease processes each molecule of the trimer into mature
surface glycoprotein (SU) and transmembrane anchor protein
(TM), which remain covalently associated via a disulfide
bridge. Heterotrimers of mature SU and TM are presented on the
plasma membranes of host cells, where they incorporate into virus
particles budding from the cell surface. Virions that do not contain
heterotrimeric envelope proteins in their membranes are not infectious
(6). When ecotropic virus particles bud from the producer
cell surface, there is a third cleavage of envelope protein in which
carboxy-terminal residues, called the R peptide, are removed to yield a
12-kDa TM that is more fusogenic than the 15-kDa TM (17, 35,
36).
Cleavage of retroviral envelope precursors into SU and TM is thought to
be essential for assembly of infectious retroviral particles
because mutations that abolish cleavage result in noninfectious particles. Frequently, the failure to cleave the envelope
precursor prevented its transport to the cell surface, presumably
because of gross misfolding, precluding its incorporation into virions (2, 3, 40). Deletion of a 20-amino-acid segment that
included the cleavage site of ecotropic Moloney MLV (MoMLV) envelope
protein resulted in the synthesis of uncleaved protein and the
production of "bald" particles lacking envelope protein
(16). Subtle changes in the cleavage site of ecotropic AKV
MLV reduced the amount of mature SU present in virions, resulting in
incorporation of very small amounts of an extraordinarily large
envelope species (100 kDa) and reducing the infectivity of virions on
NIH 3T3 cells by 100-fold but rendering them noninfectious on XC cells
(13). Mutations that altered the cleavage sites of human
immunodeficiency virus, mouse mammary tumor virus, and Rous sarcoma
virus envelope proteins did not prevent cell surface presentation of
the uncleaved precursors but resulted in complete loss of infection,
even though virions of one of the Rous sarcoma virus mutants contained
appreciable amounts of precursor protein (8, 9, 15, 18). One
exception has been reported. Uncleaved envelope proteins were reported
on virions from a spontaneous, infectious mutant of ecotropic Rauscher MLV, although the exact mutation(s) responsible for this phenomenon was
not identified (27).
In addition, cleavage of the precursor protein is thought to be
essential for assembly of infectious particles because it frees a
stretch of hydrophobic residues at the amino terminus of TM (6,
32). Mutations in this sequence result in the loss of infection
and a loss of the ability of a retrovirus to induce fusion of two
adjacent cells bearing virus receptors, suggesting that these residues
comprise a fusion peptide (4, 12, 22, 43). Cleavage just
upstream of such an internal fusion peptide in the envelope proteins of
other viruses, such as influenza virus, is a prerequisite for their
role in penetration of the host cell (42). By analogy to the
model for influenza virus entry, binding of the envelope protein to the
virus receptor triggers a change in the conformation of the fusion
peptide, swinging it approximately 180 degrees to intrude into the host
cell membrane for formation of a pore through which the core of the
virus is passed (5). Such a dramatic change in the structure
of the envelope protein would be difficult, if at all possible, if the
fusion peptide remained covalently secured to the carboxy-terminal
portion of the surface protein as it is in the envelope precursor.
The association of SU and TM after cleavage is tenuous. The disulfide
bridge connecting them is labile and is readily disrupted by the
mechanical stress, such as freezing and thawing (21, 26),
that occurs during storage of retrovirus stocks. Disruption of this
covalent linkage causes SU to dissociate or shed from the surfaces of
virus particles, leaving them noninfectious. The association of SU and
TM is also destabilized by insertion of foreign sequences into the
envelope protein, such as by the fusion of a binding domain from a
heterologous ligand for the production of a hybrid envelope protein
that directs virus attachment and infection to specific cell types for
targeted gene delivery (7).
Infection begins with binding of SU protein to the virus receptor on
the plasma membrane of a host cell. At least one region consisting of
approximately the first 200 residues in SU is essential for recognition
of the ecotropic retrovirus receptor (20). Only a few
critical residues within this domain have been identified. Aspartate 84 and arginines at positions 83 and 95 appear to be required for receptor
binding (2, 28). In addition, three pairs of positively
charged arginine and lysine residues at positions 102 and 104, 124 and
126, and 223 and 225 appear to play an as yet undetermined role in
virus infection (39).
The virus attachment site lies within the third extracellular loop of
the receptor, a polytopic membrane protein that normally functions as
the principal transporter of cationic amino acids in the host cell
(1a, 24). We previously showed that within this binding site
tyrosine 235 provides a critical hydrophobic side chain and that
glutamate 237 provides a critical side chain carboxyl group
(29). Moreover, we noted that a similar motif of a
hydrophobic amino acid and a nearby charged residue has been found in
the virus binding sites of other retrovirus receptors (29).
Here we report the use of site-directed mutagenesis to identify
important functional residues on SU, in an attempt to locate those that
bind the critical glutamate residue on the receptor. Unexpectedly, we
identified a number of novel envelope cleavage mutant proteins.
Remarkably, suppression of cleavage in four of the mutant proteins did
not prevent efficient incorporation of the envelope precursor into
virus particles. Moreover, virions containing the precursor molecules
were highly infectious. We also identified a residue whose replacement
results in a cleavage mutant protein that is virtually noninfectious.
These virions contained the envelope precursor but no detectable mature
SU. Particles containing each of the envelope cleavage mutant proteins showed marked losses of receptor binding. These results indicate that
the residues altered in the cleavage mutant proteins are involved in
correct folding of the cleavage recognition and receptor binding sites.
They also indicate that cleavage of the envelope precursor into mature
SU and TM is not necessary for assembly into virus particles.
Furthermore, virions coated with precursor protein can be highly
infectious, suggesting that only a few molecules of free fusion peptide
are required to complete virus fusion. Inclusion of these cleavage
mutations into the retroviral envelope proteins on targeted retroviral
vectors should prevent loss of the modified surface proteins from
virions, improving their infectivity and storage hardiness.
 |
MATERIALS AND METHODS |
Cell lines and viruses.
All cell lines were maintained at
37°C in 5% CO2. Mouse NIH 3T3 fibroblasts and
nonpermissive human 293 fetal kidney cells were cultured in Dulbecco's
modified Eagle's medium supplemented with 8% donor calf serum. The
293 cell-derived stable transfectant expressing the receptor cDNA has
been described elsewhere (29). These cells and
virus-producer H1-BAG cells were maintained in Dulbecco's modified
Eagle's medium with 8% fetal bovine serum and 250 µg of G418
(Sigma) per ml.
Plasmids bearing virus genomes.
Initially, we constructed a
master plasmid, pcDNA-MoMLV, bearing a virus genome derived from
ecotropic MoMLV that provides wild-type gag and
pol genes, from which proteins for the virion core were
made, and an env gene, from which the envelope proteins for
assembly into the membrane of the virions were synthesized. The 8-kbp
fragment from the BssHII restriction site to the
env termination codon containing the MoMLV proviral genome
that lacks the packaging signal was derived from plasmid pEM-5 (gift of
V. Garcia). The env gene termination codon is followed by an
artificially engineered BamHI site. The genome was inserted
between the HindIII and BamHI sites of the
eukaryotic expression vector pcDNA3 (Invitrogen), which resulted in
transcription of the viral genome being placed under the control of the
cytomegalovirus promoter and a downstream polyadenylation site being
provided by the bovine growth hormone poly(A). This genome is not
incorporated into virions because it lacks the encapsidation sequence,
. It also lacks the U3 region of the 5' long terminal repeat and the
entire 3' long terminal repeat. Envelope gene fragments containing
specific mutations were subcloned into the HpaI sites in
pcDNA-MoMLV for production of virions.
Virus production.
The amphotropic packaging cell line PA317
(33) was transiently transfected by calcium phosphate
precipitation with the pBAG plasmid (gift of C. Cepko) (41),
which bears a replication-defective but packageable MoMLV genome in
which the structural genes were replaced by the Escherichia coli
lacZ gene and the neomycin resistance gene (neo). The
virus-containing supernatant was harvested and used to infect human 293 cells, into which the virus transduced the lacZ and
neo genes. Infected 293 cells were selected in the medium
containing 1 mg of G418 per ml. Twenty-four drug-resistant colonies
were propagated and analyzed for
-galactosidase expression by
staining with
5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside (X-Gal).
The five clones developing the most intense staining in the shortest
period, indicative of high levels of transcription of the virus genome,
were selected as virus producers. Expression of packageable viral RNA
was confirmed by Northern blot analysis (data not shown). One of these
cell clones, H1-BAG, was used in all experiments reported here.
To produce virus particles, we transiently transfected the H1-BAG cells
with pcDNA-MoMLV DNA containing wild-type or mutated env
genes using calcium phosphate precipitation (38).
Virus-containing supernatant was freed of producer cells by low-speed
centrifugation followed by filtration through a 0.45-µm-pore-size
filter. An aliquot of 3 ml was removed, stored at
80°C, and then
used for virus titration. Viruses from the remaining 7 ml were
immediately pelleted as described below for immunoblotting. For each
virus binding experiment, the entire virus preparations were frozen and
concentrated as described below. Virions produced in this manner
transduce
-galactosidase activity upon infection of cells.
Site-directed mutagenesis of env genes.
Nucleotide substitutions in the env gene were generated by
the method described by Kunkel (25). The envelope residues
whose codons were mutagenized are indicated by their positions in the MoMLV envelope protein; the alanine residue at the N terminus of mature
SU was considered residue 1. For this purpose we subcloned the 1,300-bp
HpaI-HpaI restriction fragment from the MoMLV
env gene on plasmid pMOV3 (gift of H. Stuhlmann)
(19) into the bacteriophage vector M13mp18 with an
engineered HpaI site. Site-directed mutagenesis was
performed, and the fragment was transferred to pcDNA3-MoMLV. The entire
1,300-bp fragment was sequenced with an fmol sequencing kit (Promega),
with the resulting plasmid being used as a template to ensure the
absence of unscheduled substitutions and to confirm the presence of
desired mutations.
Virus titers.
Endpoint dilution titration of all virus
stocks was performed essentially as previously described for ecotropic
MLV (29) with modifications as follows. Briefly, 2 × 104 cells were seeded in each well of 24-well culture
plates, and quadruplicate wells were exposed to 10-fold serial
dilutions of virus stock in medium containing Polybrene (20 µg/ml;
Sigma). Forty-eight hours after exposure, cells were fixed and stained with X-Gal for
-galactosidase activity. Titers were calculated for
the endpoint dilution. Every titration included exposure of straight
virus stocks and a 10
1 dilution into parental human 293 cells lacking an ecotropic receptor. We did not observe entry by any
mutant or wild-type virus into the parental 293 cells in any of the
titrations, indicating that the entry reported for the human 293 cell
line stably expressing the ecotropic receptor did not occur by a
non-receptor-mediated pathway.
Western blot analysis.
Virus particles were pelleted from 7 ml of cell-free virus supernatant through 3 ml of 25% sucrose in TEN
(10 mM Tris [pH 8.0], 1 mM EDTA, 100 mM NaCl) in a Beckman SW41 rotor
(30,000 rpm, 2 h, 4°C). Pellets were taken up in 40 µl of
phosphate-buffered saline. Virus producer cells were lysed immediately
after virus harvest in 300 µl of RIPA buffer (20 mM Tris [pH 7.0],
1% Triton X-100, 0.05% sodium dodecyl sulfate [SDS], 0.5% Na
deoxycholate, 150 mM NaCl, 2.5 mM phenylmethylsulfonyl fluoride) by
incubation for 30 min on ice. Cell lysates were obtained after
pelleting nuclei by centrifugation in an Eppendorf model 5415C
centrifuge for 10 min at 10,000 rpm. Total protein concentrations in
cell lysates were determined by the Bradford assay (Bio-Rad). Ten
microliters of virus pellets or 100 µg of total protein from cell
lysates was diluted 1:1 in 2× gel loading buffer (38),
boiled, and subjected to SDS-polyacrylamide gel electrophoresis, and
the separated proteins were transferred onto a nitrocellulose membrane
(Protran; Schleicher & Schuell) or Immobilon (Millipore). Envelope
proteins (SU and precursor) were detected with goat anti-Rauscher-gp70
antiserum (1:100, identification no. 80S000018; Quality Biotech Inc.),
structural capsid protein (CA) was detected with goat anti-Rauscher-p30
antiserum (1:10,000, identification no. 81S000263; Quality Biotech
Inc.), and envelope TM protein was detected with rabbit anti-p15E
antiserum (1:250; gift of Alan Rein). Membranes from subsequent
incubation with mouse anti-goat or mouse anti-rabbit antiserum
conjugated to horseradish peroxidase (1:10,000; Sigma) were developed
with a chemiluminescent substrate from a Renaissance kit (NEN).
Virus binding assays.
Binding assays were performed
essentially as described previously (7, 23) with the
following modifications. Virus-containing supernatants were
concentrated 10- to 15-fold on Centricon-100 concentrators (Amicon).
Concentration promotes binding of multiple virions to a single cell,
increasing the mean fluorescence per cell (45), and
eliminates most of the free SU protein. To ensure that equal numbers of
particles from each of the virus stocks were incubated with cells
during the assay, the concentration of virus stocks was adjusted to
achieve comparable particle concentrations based on the reverse
transcriptase activity and Western blot quantitation of capsid protein
(data not shown). Human 293 cells (106) expressing the
wild-type virus receptor or parental 293 cells were detached from
culture plates with phosphate-buffered saline containing 0.02% EDTA
and then incubated with 1 ml of concentrated virus stocks containing
equal amounts of virions in the presence of Polybrene (5 µg/ml) for
1 h at 4°C. Cells and bound virus were incubated with goat
anti-gp70 antiserum (1:100) for 30 min at 4°C and then with donkey
anti-goat antiserum conjugated to fluorescein isothiocyanate (1:200;
Jackson Laboratories) for 30 min at 4°C. Propidium iodide (Sigma) was
added to the binding reaction mixture for 5 min at a final
concentration of 20 µg/ml. The fluorescence of 5,000 live cells
(negative for propidium iodide) was analyzed by flow cytometry (Epics
Profile Analyzer; Coulter Cytometry). Experiments were repeated two times.
 |
RESULTS |
In these studies, we attempted to identify residues on the virus
envelope proteins that interact with critical residue glutamate 237 in
the putative virus-binding site on the receptor. We previously proposed
that the negatively charged carboxyl group on the side chain of
glutamate 237 participates in a salt bridge with a positively charged
side chain of a lysine or arginine residue on the virus SU
(29). To test this hypothesis, we examined the effect of replacing positively charged residues in SU with amino acids having negatively charged side chains or with alanine. We focused on lysine
111, arginine 149, and lysine 153 (envelope residues are numbered
beginning with the alanine residue at the N terminus of mature SU
[residue 1]). In addition, we examined the three pairs of arginines
and lysines previously identified by Skov and Andersen as critical for
virus infection, i.e., arginine 102 and lysine 104, arginines 124 and
126, and arginines 223 and 225 (39). We also examined the
effect of replacing a negatively charged amino acid, aspartate 135, because it is conserved in SUs from a number of retroviruses that use
receptors other than the ecotropic receptor.
Stocks of virus assembled from wild-type gag and
pol gene products and wild-type or mutant env
gene products were produced by transient transfection of pcDNA-MoMLV
into human 293 cells stably expressing the pBAG retroviral genome.
Mutant virus stocks that contained levels of CA comparable to that in
the wild-type virus stocks (indicative of equivalent transfection
efficiencies and levels of virus particle production) were analyzed by
endpoint dilution titration for their ability to infect host cells and by Western blot analysis for envelope protein incorporation. Envelope protein processing was assessed by Western blot analysis of the lysates
from the transfected human cells. Selected virus stocks were also
analyzed for receptor binding by flow cytometry. To determine if the
high-molecular-weight protein species found in virions was the envelope
precursor or hyperglycosylated mature SU, selected stocks were also
analyzed for the presence of TM sequences in the putative precursor
species, as well as for the size of the envelope protein after
treatment with glycosidase F.
Replacement of arginine 102 resulted in incorporation of a putative
envelope precursor protein into virus particles.
Replacement of
arginine 102 with alanine (R102A), aspartate (R102D), or glutamate
(R102E) almost completely abolished virus infection of mouse NIH 3T3
fibroblasts and of human 293 cells stably expressing the exogeneous
ecotropic virus receptor (Fig. 1A).
Surprisingly, these virions contained a protein species the size of the
envelope precursor (85 kDa) that reacted with anti-SU antiserum; no
species the size of mature SU (70 kDa) was detected in virions (Fig.
1B). The producer cells from which the viruses had been harvested did
not contain detectable amounts of mature SU either (Fig. 1C). Since the
anti-SU antiserum was specific for envelope proteins (data not shown),
these results suggested that cleavage of the precursor into SU and TM
was suppressed by these substitutions. More importantly, if the 85-kDa
species represented uncleaved envelope protein, then these results
indicate that the envelope precursor can be assembled into virions,
albeit poorly in the mutant virions, particularly in that containing
the alanine substitution.

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 1.
Substitution of amino acids at positions 102 and 104 appear to suppress envelope precursor protein cleavage but do not
preclude putative envelope precursor incorporation into virions, and in
the case of residue 104, do not preclude a productive virus-receptor
interaction. Replacement of R102 abolishes virus infection, whereas
viruses remain highly infectious upon replacement of K104.
Substitutions at positions 111 and 114 do not influence envelope
protein processing or virus infectivity. (A) Naive NIH 3T3 cells
(stippled bars) and human 293 cells stably expressing the wild-type
ecotropic receptor (black bars) were exposed to 10-fold serial
dilutions of stocks of virions pseudotyped with envelope proteins
containing the indicated substitutions. Each value is the average of
results of five independent experiments. MoMLV, wild-type ecotropic
MoMLV. Titers were calculated from the endpoint dilution (n = 4). (B) Western blot analysis of virions containing mutant
env genes. Proteins were separated on 8% acrylamide gels.
The membrane was cut into two parts at the position indicated by the
black line (approximately 45 kDa). The top portion was incubated with
anti-SU antiserum, and the bottom part was incubated with anti-CA
antiserum. Production of viruses containing mutant envelope proteins
was comparable to that of the wild-type virus, as upon short exposure
of immunoblots, the intensities of the bands corresponding to CA were
within twofold of each other in all pellets, except those from
mock-transfected cells (data not shown). The immunoblot shown is
representative of five made from independent virus preparations. (C)
Western blot analysis of virus producer cell lysates. Proteins were
separated on an 8% polyacrylamide gel, and the membrane was probed
with anti-SU antiserum.
|
|
Replacement of lysine 104 with aspartate yielded putative cleavage
mutant virions that are highly infectious.
Replacement of lysine
104 on SU with alanine or with aspartate did not alter infection of
human 293 cells stably expressing the virus receptor. These cells were
as susceptible to virions coated with a mutant protein containing the
K104D or K104A mutation as they were to virions coated with wild-type
envelope protein (Fig. 1A). NIH 3T3 cells were slightly less
susceptible to these viruses (Fig. 1A). Western blot analysis showed
that anti-SU antiserum reacted with two protein species in K104D
virions. One species was the size of mature SU, and the second species
was the size of the envelope precursor (Fig. 1B), suggesting that these
substitutions also suppress envelope protein cleavage. If the 85-kDa
species represents uncleaved envelope protein, then these results not only provide additional evidence that the precursor can be assembled into virions but, more importantly, also indicate that virions carrying
the precursor can be highly infectious.
We also analyzed the envelope protein forms in lysates of the producer
cells from which the K104D virus had been harvested.
Mature SU was not
detectable in cells producing K104D viruses,
although the precursor was
present (Fig.
1C), suggesting that
the K104D mutation is a potent
suppressor of envelope cleavage.
Interestingly, K104D virions contained
appreciable amounts of
mature SU even though steady-state levels of
mature SU were too
low to be detected in the K104D producer
cells.
Replacement of arginines 124 and 126 or arginines 223 and 225 also
results in highly infectious putative cleavage mutant virions.
Replacement of arginine 124 with glutamate (R124E) gave a phenotype
similar to that of the R102A mutant virion. Infection was dramatically
decreased and precursor cleavage was almost completely abolished by an
R124E substitution (Fig. 2). Envelope
precursor was incorporated into virions, albeit poorly. No mature SU
was detectable in virions or in producer cells. Surprisingly, virions containing an arginine 124-to-aspartate (R124D) substitution were only
slightly less infectious than were wild-type viruses, a 10,000-fold improvement over the infectivity observed for the glutamate change (Fig. 2). Both precursor and mature SU were incorporated into these
highly infectious R124D virions. As with the K104D mutant virions
contained a surprising amount of mature SU, considering that none was
detectable in producer cells. Moreover, double mutant virions with an
R124D and an R126D substitution consistently contained more precursor
molecules than mature SU (Fig. 2), suggesting that the addition of the
seemingly innocuous R126D substitution somehow enhances precursor
incorporation into virions. Furthermore, replacement of arginines 223 and 225 with aspartate (R223D R225D) also resulted in incorporation of
an 85-kDa envelope protein species, suggesting that precursor cleavage
is also suppressed by these changes (Fig. 3). Here too, the envelope precursor was
incorporated into highly infectious virions.

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 2.
Substitution of arginine 124 also appears to suppress
protein cleavage. Glutamate at this position produces noninfectious
particles, whereas aspartate produces highly infectious virions coated
with uncleaved envelope protein. Mutations at positions 126 and 135 do
not affect protein maturation and virus entry. (A) Virus titers on NIH
3T3 cells (stippled bars) and human 293 cells expressing the exogenous
wild-type receptor (black bars). Titers were calculated from the
endpoint dilution (n = 4) after exposure to virions
pseudotyped with envelope proteins containing the indicated
substitutions. Each value is the average of results from five
independent experiments. MoMLV indicates the wild-type virus. (B)
Western blot analysis of virions containing mutant env
genes. The membrane was cut at the position indicated by the black
line, and then the top portion was incubated with anti-SU antiserum and
the bottom portion was incubated with anti-CA antiserum. (C) Western
blot analysis of virus producer cell lysates with anti-SU antiserum.
|
|

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 3.
Substitutions of residues at positions 223 and 225 also
appear to suppress cleavage, resulting in highly infectious virions
coated with the putative envelope precursor. (A) Virus titers on NIH
3T3 cells (stippled bars) and human 293 cells expressing the exogenous
wild-type receptor (black bars) calculated from the endpoint dilution
(n = 4). Each value is the average of results from five
independent experiments. MoMLV, wild-type virus; mock, supernatant or
lysate of cells transfected with pcDNA3. (B) Western blot analysis of
virions with anti-SU antiserum and anti-CA antiserum. (C) Western blot
analysis of virus producer cell lysates with anti-SU antiserum.
|
|
The phenotype of a number of substitutions was indistinguishable from
that of the wild-type envelope protein. Replacement
of lysine 111 with
alanine (K111A), arginine 126 with aspartate
(R126D) or glutamate
(R126E), aspartate 135 with alanine (D135A)
or lysine (D135K), or
arginine 149 with aspartate and lysine 153
with aspartate (R149D K153D)
did not alter infection or envelope
precursor cleavage (Fig.
1 to
3).
These results suggest that those
residues are not essential to
productive virus-receptor interaction
and that they are not involved in
envelope protein
folding.
The 85-kDa protein species consisted of uncleaved envelope
precursor protein.
It was possible that the 85-kDa species present
in virions coated with mutant envelope proteins was not uncleaved
envelope precursor protein but rather a hyperglycosylated form of
mature SU. Misfolding of the envelope precursor might lead to greater than normal carbohydrate addition at any or all of the glycosylation sites. Cleavage of such a hyperglycosylated precursor would then yield
mature SU that by coincidence was the size of the precursor with normal
glycosylation. If this was the case, then removal of carbohydrates
would yield a single 52-kDa protein species representing unglycosylated SU. If the size difference was not due to
hyperglycosylation, then removal of carbohydrates would yield 68- and
52-kDa species representing the unglycosylated forms of the precursor
and SU, respectively.
We used wild-type producer cell lysate to assess glycosylation of
envelope proteins because it would provide precise size
standards for
the deglycosylated precursor and mature SU. We also
used the cell
lysate to determine if the glycosidase F digestion
proceeded to
completion in order to be reasonably certain that
any species detected
after glycosidase treatment was the 68-kDa
deglycosylated precursor
rather than 70-kDa molecules of mature
SU that escaped deglycosylation.
Lysate from human cells expressing
the wild-type envelope protein was
treated with excess glycosidase
F overnight, the same conditions used
to treat virions. The expected
68- and 52-kDa envelope protein species
resulted (last lane of
Fig.
4). Most
importantly, there was no detectable 85-kDa protein,
indicating that
the glycosidase reaction had proceeded to completion.
Treatment of
virions coated with the mutant envelope proteins
also yielded two
species of 68 and 52 kDa corresponding, respectively,
to the
unglycosylated precursor and SU species seen in the producer
cells
(Fig.
4). Moreover, the ratio of putative precursor species
(85 kDa) to
mature SU (70 kDa) in untreated aliquots of virions
was comparable to
the ratio of the 68-kDa species to the 52-kDa
species observed upon
deglycosylation for all mutants. The predominant
species in K104D,
R124D R126D, R124E, and R223D R225D virions
was 85 kDa prior to
digestion and 68 kDa (representing the deglycosylated
envelope
precursor) after glycosidase F digestion, whereas the
predominant
species in R124D virions were 70 kDa prior to digestion
and 52 kDa
after glycosidase F digestion. These results demonstrated
that
hyperglycosylation of mature SU was not responsible for the
85-kDa
protein species.

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 4.
The 85-kDa envelope protein species does not represent
hyperglycosylated SU. Wild-type MoMLV producer cell lysate (last lane)
or purified wild-type and mutant virions were incubated with
glycosidase F overnight, separated by SDS-polyacrylamide gel
electrophoresis on 8% gels, and then submitted to Western blot
analysis with anti-SU antiserum (top portion) and anti-CA antiserum
(bottom portion).
|
|
In addition, we determined if TM sequences were present in the 85-kDa
envelope protein species. As a positive control, we
again used
wild-type producer cell lysate. Initially, we used
monoclonal anti-TM
antibody 42-114 (
34) to detect TM sequences.
Although 42-114 readily recognized its epitope in mature TM, it
failed to recognize the
epitope when it was present in the precursor
species of wild-type
producer cell lysate under a variety of conditions
and with
nitrocellulose and nylon (Immobilon; Millipore) membranes
(last lane of
Fig.
5A). We then tried polyclonal
anti-TM antiserum
(gift of A. Rein) to detect TM sequences. No reaction
of this
anti-TM antiserum with precursor species was observed when
producer
cell lysate was transferred to nitrocellulose (data not
shown).
However, when lysate was transferred to Immobilon, it weakly
recognized
TM sequences in the precursor (second lane of Fig.
5A).
Importantly,
this antiserum did not react with mature SU (70 kDa). It
reacted
strongly with the 15-kDa species of mature TM and cross-reacted
with CA present in its precursor forms, particularly the 65-kDa
capsid
precursor, gag65 (middle lane of Fig.
5A). Because the
85-kDa species
does not contain Gag- or CA-specific sequences
(data not shown), we
could still use this antiserum for immunoblot
analysis of the mutant
virion proteins. It weakly recognized the
85-kDa species in virions
coated with the R124D R126D, R124D,
R124E, R223D R225D, and K104D
putative envelope cleavage mutant
proteins, in addition to reacting
with mature TM (15 and 12 kDa),
the 65-kDa capsid precursor, and mature
CA (left membrane of Fig.
5B). Notably, the antiserum consistently
reacted more strongly
with the sparsely incorporated precursor species
of the R124D,
R124E, and R223E R225D mutant proteins than with the
abundantly
incorporated precursor species of the R124D R126D and K104D
mutant
proteins. We do not know the cause of this variation but suspect
that the principal epitopes that this antiserum recognizes tend
to bind
to the membrane when TM remains covalently bonded to SU,
so that they
are unavailable for antibody binding. In R124D, R124E,
and R223D R225D
mutant proteins, these epitopes appear to be more
accessible for
unknown reasons. Only mature TM and the CA forms
were recognized in
wild-type virions. These results demonstrate
that the 85-kDa species
that was incorporated into these mutant
virions were envelope precursor
protein, establishing that these
mutations suppress envelope protein
cleavage.

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 5.
Immunoblot analysis of virions with anti-TM antiserum
confirmed that mutant virions contained the uncleaved envelope
precursor. (A) Replicate samples of wild-type producer cell lysate were
separated on a 6 to 15% polyacrylamide gradient SDS gel and
transferred to an Immobilon membrane; lanes were then cut apart and
reacted with monoclonal anti-TM 42/114 (last lane), anti-TM (middle
lane), or anti-SU (first lane) antiserum. (B) Wild-type and mutant
virion proteins were separated on 6 to 15% polyacrylamide gradient SDS
gels and transferred to Immobilon membranes. Membranes were analyzed
first by incubation with anti-TM antiserum (left membrane) and then
deprobed and reacted with anti-SU antiserum (right membrane). gag 65, the 65-kDa capsid precursor.
|
|
Virus particles coated with mutant envelope precursor proteins were
deficient in receptor binding.
To determine if any of the
mutations affected receptor binding, we performed equilibrium virus
binding assays. Under conditions where 107 infectious units
corresponding to approximately 109 physical particles
(44) were incubated with 106 host cells, we
observed a 50-fold increase in mean fluorescence intensity upon
incubation of susceptible host cells expressing the receptor with MoMLV
over the level of fluorescence intensity upon incubation with
nonsusceptible cells lacking the receptor (Fig.
6). As an additional positive control, we
measured receptor binding of the D135A virions that did not exhibit any
detectable differences in levels of envelope processing or
incorporation and that were as infectious as the wild-type virus. We
observed a 60-fold increase in mean fluorescence for these viruses.
Remarkably, host cells incubated with R223D R225D particles exhibited
only a 2-fold increase in mean fluorescence
25-fold less than that of
the wild-type virus
even though they were only 20-fold less infectious
than the wild-type virus. Highly infectious particles coated with the
K104D, R124D R126D, and R124D mutant proteins exhibited only 9- to
10-fold increases (Fig. 6), indicating that receptor binding of these
mutant virions was reduced by >5-fold compared with that of the
wild-type or D135A virus. The R124E mutant virions exhibited a
6.6-fold-higher level of mean fluorescence and a 7.6-fold-lower level
of equilibrium binding to the virus receptor than the levels of the
wild-type virus and 1.5-fold-lower levels than those of the highly
infectious R124D virions. These results suggested that the longer side
chain of glutamate results in a more marked change in the structure of
the receptor binding domain than does the side chain of aspartate. In
agreement with this, the R124E substitution produced a more profound
suppression of cleavage than did the R124D substitution. It does not
appear that the 1.5-fold reduction in binding of R124E virions over
that of R124D virions accounts for their dramatic difference in
infection since the R223D R225D virions exhibited an even greater loss
of receptor binding without a concomitant loss of infection. It is more
likely that the difference in infectivity is due to greater incorporation of mature SU and TM in R124D virions.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 6.
Virions coated with envelope cleavage mutants bind the
ecotropic virus receptor inefficiently. Purified virions were incubated
with human 293 cells stably expressing the exogenous ecotropic virus
receptor and then with goat anti-SU antiserum and mouse anti-goat
antiserum conjugated to fluorescein isothiocyanate. Last, virus
cell-antibody complexes were incubated with propidium iodide. Bound
virus was quantified by measuring the mean fluorescence intensity of
live cells (those cells lacking propidium iodide staining) by flow
cytometry. "No receptor" indicates parental human 293 cells not
expressing the exogenous receptor incubated with wild-type MoMLV and
antibodies; "No virus" indicates 293 cells stably expressing the
exogenous receptor incubated with antibodies alone. The mean
fluorescence intensity of the no receptor peak was 0.5, and that of the
no virus peak was 0.6. Infectivity was summarized from the data in Fig.
1 to 3. +, infectious titer within 100-fold of that of wild-type MoMLV;
, infectious titer >10,000-fold less than that of wild-type MoMLV.
|
|
It was possible that the cleavage mutations caused dissociation of SU
from TM. If this was the case, virions might have lacked
mature SU
because it was shed during pelleting through the sucrose
cushion prior
to immunoblotting or during concentration prior
to binding assays. This
is particularly important because we performed
the virus titration
studies using virions directly from the producer
cell supernatant. To
determine if this was the case, we performed
immunoblot analyses on
virions that were pelleted by direct centrifugation
from the cell
supernatant (no sucrose cushion) and so contained
virion-associated,
plus shedded, SU from the cell supernatant.
We then evaluated shedded
SU by comparing the amounts of mature
SU in these samples to those
found in virions after they were
pelleted through sucrose; any
difference would indicate that a
mutation caused shedding that might
account for the pausity of
SU in mutant virions. After being pelleted
through sucrose, mutant
and wild-type virions contained amounts of
mature SU comparable
to those found in cell supernatants pelleted
directly (data not
shown), indicating that none of the cleavage
mutations led to
detectable SU shedding. The cell supernatant pellets
also showed
that mature SU was undetectable or greatly reduced and that
the
85-kDa precursor was the predominant envelope species in the
cleavage
mutants.
 |
DISCUSSION |
Incorporation of envelope precursor protein does not preclude
productive virus-receptor interaction.
It was previously thought
that cleavage of the precursor into mature SU and TM was required for
assembly of envelope proteins into retroviral particles. However, we
identified two types of novel envelope cleavage mutant proteins, each
exhibiting some degree of failure to cleave precursor protein into
mature SU and TM accompanied by assembly of precursor into virions. The
first type resulted in a slight reduction of infectivity (10- to
100-fold), while the second type contained changes that resulted in a
>10,000-fold loss of infectivity. These data provide evidence that
cleavage is not a prerequisite for envelope protein transport to the
cell surface and assembly into virus particles. Moreover, virions
containing predominantly precursor protein can support productive
virus-receptor interactions.
We cannot make definitive conclusions as to whether the altered
residues interact directly with the receptor. The failure
of host cell
proteases to cleave precursors in mutant proteins
containing
substitutions that are distal to the actual site of
cleavage suggests
that these envelope precursors are misfolded.
Hence, the defect in
virus-receptor binding is most likely attributable
to incorrect
conformation of envelope
proteins.
Mature SU and TM appear to be the preferred substrates for virion
assembly.
K104D virions consistently contained the envelope
precursor and less of the mature SU, whereas, cells producing these
viruses contained detectable levels of precursor but not mature SU.
Interestingly, K104D, R124D, and R124D R126D virions also contained
appreciable amounts of mature SU even though steady-state levels of
mature SU were too low to be detected in their respective producer
cells. These results suggest that although the precursor can be
incorporated, the cleaved envelope proteins are the preferred substrate
for assembly into virions. Alternatively, the suppression of precursor cleavage may be somewhat relieved during or after virion assembly by
changes in envelope protein conformation so that secreted cellular proteases can perform the cleavage that normally occurs in the Golgi apparatus.
Only a few molecules of mature TM appear to be required to mediate
virus entry.
In all but two cases, the infectivities of the
cleavage mutant viruses correlated with the amounts of mature SU
present on virions regardless of the amount of precursor protein
present. Mutants that were highly infectious contained appreciable
amounts of mature SU and TM in addition to the precursor, whereas
mutants that were poorly infectious contained undetectable amounts of mature SU and TM. It is likely that the observed infection was accomplished by free fusion peptide on a relatively small number of
cleaved envelope molecules incorporated into virions acting in
trans after being bound by the uncleaved precursor
molecules. Recent studies have shown that monomers within the envelope
trimer can cooperate in trans to accomplish virus entry
(37, 46). However, we cannot rule out the possibility that
infection by some mutant virions was mediated by a constrained fusion
peptide that was able to function in the context of the appropriate
changes in SU. For example, the envelope protein of vesicular
stomatitis virus contains an internal fusion peptide that remains
constrained during virus entry (11).
We consistently observed 10- to 50-fold-lower infectious titers of
cleavage mutant stocks on NIH 3T3 cells than on human 293
cells stably
expressing the ecotropic receptor. This difference
may be the result of
the greater number of virus receptors available
on 293-ecotropic
receptor cells. These cells express three to
four times as many virus
binding sites as do NIH 3T3 cells (
1b).
However, NIH 3T3
cells also appear to be less fusogenic in that
they are naturally
resistant to cell-cell fusion in the presence
of high-titer wild-type
MoMLV stocks (
31), whereas the human
293-ecotropic receptor
cells readily fuse (
1). Thus, the difference
in
susceptibilities to cleavage mutant viruses might be the result
of the
less fusogenic NIH 3T3 cells requiring more molecules of
free fusion
peptide to efficiently complete virus entry than 293-receptor
cells
require.
Interestingly, the weaker band intensity observed with the anti-TM
antiserum revealed that the 85-kDa species is actually
a doublet, a
fact that was likely obscured by the intensity of
these species when
they were reacted with anti-SU. This result
brings up the possibilities
that the higher-molecular-mass species
represents the intact precursor
and that the slightly faster-migrating
species represents the precursor
from which R peptide has been
removed. Indeed, the small amounts of
mature TM detected in the
virions coated with mutant proteins was the
12-kDa, R-less species,
indicating that these mutant proteins receive
this cleavage as
particles mature. Alternatively, it is possible that
the two species
represent differences in levels of glycosylation of the
precursors
found in
virions.
Receptor binding might not be the rate-limiting step in MoMLV
entry.
Structural changes resulting from a number of substitutions
affected receptor binding. Remarkably, for entry, most of the cleavage
mutant virions could tolerate as much as 5- to 25-fold reductions in
the levels of equilibrium binding to the receptors on host cells
without experiencing more than a 100-fold reduction in infection. These
results suggest that virus binding to the receptor might not be the
rate-limiting step in retroviral entry. They also suggest that
efficient virus binding is not required for entry of at least these
mutant virions and raise the question of whether the same is true for
the wild-type virus. No infection data or measurements of the relative
levels of binding efficiency of particles containing various amounts of
wild-type envelope protein are available to address this question.
Determining its answer should provide important insights as to the
numbers of envelope molecules and receptors required for productive
infection of retroviruses.
A possible mechanism for suppression of SU-TM cleavage by
substitutions at residues 102, 104, 124, 126, 223, and 225.
Our
results suggest that the residues altered in the cleavage mutant
proteins can influence the folding of the cleavage recognition site. In
the crystal structure of amino acids 9 through 236 of SU from ecotropic
Friend MLV (10), the residues that correspond to all but two
of the cleavage mutations are at the "top" along the surface that
has been proposed to be the receptor binding site since it contains the
residue corresponding to MoMLV aspartate 84 (10). If this is
the surface that makes the initial contact with the receptor, then it
would be expected to act like a sensor, transducing changes occurring
upon receptor binding through the
-sandwich of the binding domain
into the carboxy-terminal region of SU and then into TM to activate
fusion peptide function. Mutations that produce structural changes
mimicking those occurring during interaction with the receptor might be
expected to translate through the protein to change folding of these
same domains, including that of the cleavage recognition site between
arginine 436 and glutamate 437 of the precursor. Arginines 223 and 225, the two sites we altered that were not on the receptor binding surface, are near the base of the
-sandwich. Their replacement by aspartate residues might create similar conformational changes, sequestering the
cleavage site. It is striking that as great as a 25-fold decrease in
binding of R223D R225D virions over that of wild-type virions was
sufficient to support almost as efficient an entry as that of the
wild-type virus. It might be that repulsion of the side chain carboxyl
groups of the aspartates at positions 223 and 225 disturbs the
orientation of the
-sandwich, creating a rearrangement in the
envelope oligomers similar to that induced by receptor binding. The
resulting "conformational intermediate" might be a more
entry-competent molecule in that a single receptor binding event would
be sufficient to induce it to undergo all conformational changes
required for virus entry.
Retroviral vectors designed for use in human gene therapy employ
chimeric or hybrid envelope proteins to redirect virus binding
to a
protein or to a chemical moiety found uniquely on the type
of cell that
is the target for gene delivery (
14). Virions containing
these modified envelope proteins are poorly infectious or completely
noninfectious. It has been proposed that conformational changes
in
modified envelope proteins cause excessive loss of the hybrid
surface
protein (
7,
30). Furthermore, use of any retroviral
vector
for gene therapy will require storage at low temperature,
which
disrupts the tenuous association of SU with TM, resulting
in SU
shedding upon thawing. Inclusion of these cleavage mutations
into the
retroviral envelope proteins on targeted retroviral vectors
may prevent
loss of the modified surface proteins from virions
due to shedding,
improving their infectivity and storage hardiness.
In these virus
particles, the loss of receptor binding resulting
from the cleavage
mutations might well be innocuous since only
rodent cells express a
functional ecotropic virus
receptor.
 |
ACKNOWLEDGMENTS |
We thank Alan Rein for providing the anti-TM antiserum and Krish
Kizhatil, Zhaohui Qian, and Byoung Ryu for critical readings of the manuscript.
This work was supported by Public Health Service grant AI33410 from the
National Institutes of Health (to L.M.A.).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology & Immunology, University of Tennessee
Memphis, 858 Madison Ave., Rm. 101, Memphis, TN 38163. Phone: (901) 448-5521. Fax: (901) 448-8462. E-mail: lalbritton{at}utmem.edu.
 |
REFERENCES |
| 1.
| Albritton, L. M. Unpublished
observations.
|
| 1a.
|
Albritton, L. M.,
J. W. Kim,
L. Tseng, and J. M. Cunningham.
1993.
Envelope-binding domain in the cationic amino acid transporter determines the host range of ecotropic murine retroviruses.
J. Virol.
67:2091-2096[Abstract/Free Full Text].
|
| 1b.
| Albritton, L. M., and K. Kizhatil. Unpublished
data.
|
| 2.
|
Bae, Y.,
S. M. Kingsman, and A. J. Kingsman.
1997.
Functional dissection of the Moloney murine leukemia virus envelope protein gp70.
J. Virol.
71:2092-2099[Abstract].
|
| 3.
|
Berkowitz, R. D., and S. P. Goff.
1993.
Point mutations in Moloney murine leukemia virus envelope protein: effects on infectivity, virion association, and superinfection resistance.
Virology
196:748-757[Medline].
|
| 4.
|
Bosch, M. L.,
P. L. Earl,
K. Fargnoli,
S. Picciafuoco,
F. Giombini,
F. Wong-Staal, and G. Franchini.
1989.
Identification of the fusion peptide of primate immunodeficiency viruses.
Science
244:694-697[Abstract/Free Full Text].
|
| 5.
|
Bullough, P. A.,
F. M. Hughson,
J. J. Skehel, and D. C. Wiley.
1994.
Structure of influenza haemagglutinin at the pH of membrane fusion.
Nature
371:37-43[Medline].
|
| 6.
|
Coffin, J. M.,
S. H. Hughes, and H. E. Varmus.
1997.
Retroviruses.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 7.
|
Cosset, F. L.,
F. J. Morling,
Y. Takeuchi,
R. A. Weiss,
M. K. L. Collins, and S. J. Russell.
1995.
Retroviral retargeting by envelopes expressing an N-terminal binding domain.
J. Virol.
69:6314-6322[Abstract].
|
| 8.
|
Dong, J. Y.,
J. W. Dubay,
L. G. Perez, and E. Hunter.
1992.
Mutations within the proteolytic cleavage site of the Rous sarcoma virus glycoprotein define a requirement for dibasic residues for intracellular cleavage.
J. Virol.
66:865-874[Abstract/Free Full Text].
|
| 9.
|
Dubay, J. W.,
S. R. Dubay,
H. J. Shin, and E. Hunter.
1995.
Analysis of the cleavage site of the human immunodeficiency virus type 1 glycoprotein: requirement of precursor cleavage for glycoprotein incorporation.
J. Virol.
69:4675-4682[Abstract].
|
| 10.
|
Fass, D.,
R. A. Davey,
C. A. Hamson,
P. S. Kim,
J. M. Cunningham, and J. M. Berger.
1997.
Structure of a murine leukemia virus receptor-binding glycoprotein at 2.0 angstrom resolution.
Science
277:1662-1666[Abstract/Free Full Text].
|
| 11.
|
Fields, B. N.,
D. M. Knipe,
P. M. Howley,
R. M. Chanock,
J. L. Melnick,
T. P. Monath,
B. Roizman, and S. E. Straus.
1996.
Fields virology, vol. 1.
Lippincott-Raven, Philadelphia, Pa.
|
| 12.
|
Freed, E. O.,
D. J. Myers, and R. Risser.
1990.
Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41.
Proc. Natl. Acad. Sci. USA
87:4650-4654[Abstract/Free Full Text].
|
| 13.
|
Freed, E. O., and R. Risser.
1987.
The role of envelope glycoprotein processing in murine leukemia virus infection.
J. Virol.
61:2852-2856[Abstract/Free Full Text].
|
| 14.
|
Friedmann, T.
1997.
Overcoming the obstacles to gene therapy.
Sci. Am.
276:96-101[Medline].
|
| 15.
|
Goodman, L. J.,
S. R. Kain, and G. L. Firestone.
1993.
Trafficking of wild-type and an endoproteolytic-site mutant of the mouse mammary tumor virus glycoprotein.
J. Biol. Chem.
268:2329-2336[Abstract/Free Full Text].
|
| 16.
|
Granowitz, C.,
J. Colicelli, and S. P. Goff.
1991.
Analysis of mutations in the envelope gene of Moloney murine leukemia virus: separation of infectivity from superinfection resistance.
Virology
183:545-554[Medline].
|
| 17.
|
Green, N.,
T. M. Shinnick,
O. Witte,
A. Ponticelli,
J. G. Sutcliffe, and R. A. Lerner.
1981.
Sequence-specific antibodies show that maturation of Moloney leukemia virus envelope polyprotein involves removal of a COOH-terminal peptide.
Proc. Natl. Acad. Sci. USA
78:6023-6027[Abstract/Free Full Text].
|
| 18.
|
Guo, H. G.,
F. M. Veronese,
E. Tschachler,
R. Pal,
V. S. Kalyanaraman,
R. C. Gallo, and M. S. Reitz, Jr.
1990.
Characterization of an HIV-1 point mutant blocked in envelope glycoprotein cleavage.
Virology
174:217-224[Medline].
|
| 19.
|
Harbers, K.,
A. Schnieke,
H. Stuhlman,
D. Jahner, and R. Jaenish.
1981.
DNA methylation and gene expression: endogenous retroviral genome becomes infectious after molecular cloning.
Proc. Natl. Acad. Sci. USA
78:7609-7613[Abstract/Free Full Text].
|
| 20.
|
Heard, J., and O. Danos.
1991.
An amino-terminal fragment of the Friend murine leukemia virus binds the ecotropic receptor.
J. Virol.
65:4026-4032[Abstract/Free Full Text].
|
| 21.
|
Johnson, P., and M. Rosner.
1986.
Characterization of murine-specific leukemia virus receptor from L cells.
J. Virol.
58:900-908[Abstract/Free Full Text].
|
| 22.
|
Jones, J. S., and R. Risser.
1993.
Cell fusion induced by the murine leukemia virus envelope glycoprotein.
J. Virol.
67:67-74[Abstract/Free Full Text].
|
| 23.
|
Kadan, M. J.,
S. Sturm,
W. F. Anderson, and M. A. Eglitis.
1992.
Detection of receptor-specific murine leukemia virus binding to cells by immunofluorescence analysis.
J. Virol.
66:2281-2287[Abstract/Free Full Text].
|
| 24.
|
Kim, J. W.,
E. I. Closs,
L. M. Albritton, and J. M. Cunningham.
1991.
Transport of cationic amino acids by the mouse ecotropic retrovirus receptor.
Nature
352:725-728[Medline].
|
| 25.
|
Kunkel, T. A.
1985.
Rapid and efficient site specific mutagenesis without phenotypic selection.
Proc. Natl. Acad. Sci. USA
82:477-492.
|
| 26.
|
Linder, M.,
V. Wenzel,
D. Linder, and S. Stirm.
1994.
Structural elements in glycoprotein 70 from polytropic Friend mink cell focus-inducing virus and glycoprotein 71 from ecotropic Friend murine leukemia virus, as defined by disulfide-bonding pattern and limited proteolysis.
J. Virol.
68:5133-5141[Abstract/Free Full Text].
|
| 27.
|
Machida, C. A., and D. Kabat.
1982.
Role of partial proteolysis in processing murine leukemia virus membrane envelope glycoproteins to the cell surface. A viral mutant with uncleaved glycoprotein.
J. Biol. Chem.
257:14018-14022[Abstract/Free Full Text].
|
| 28.
|
MacKrell, A. J.,
N. W. Soong,
C. M. Curtis, and W. F. Anderson.
1996.
Identification of a subdomain in the Moloney murine leukemia virus envelope protein involved in receptor binding.
J. Virol.
70:1768-1774[Abstract].
|
| 29.
|
Malhotra, S.,
A. G. Scott,
T. Zavorotinskaya, and L. M. Albritton.
1996.
Analysis of the murine ecotropic leukemia virus receptor reveals a common biochemical determinant on diverse cell surface receptors that is essential to retrovirus entry.
J. Virol.
70:321-326[Abstract].
|
| 30.
|
Marin, M.,
D. Noel,
S. Valsesia-Wittman,
F. Brockly,
M. Etienne-Julan,
S. Russell,
F. L. Cosset, and M. Piechaczyk.
1996.
Targeted infection of human cells via major histocompatibility complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins.
J. Virol.
70:2957-2962[Abstract].
|
| 31.
|
McClure, M. O.,
M. A. Sommerfelt,
M. Marsh, and R. A. Weiss.
1990.
The pH independence of mammalian retrovirus infection.
J. Gen. Virol.
71:767-773[Abstract/Free Full Text].
|
| 32.
|
McCune, J. M.,
L. B. Rabin,
M. B. Feinberg,
M. Lieberman,
J. C. Kosek,
G. R. Reyes, and I. L. Weissman.
1988.
Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus.
Cell
53:55-67[Medline].
|
| 33.
|
Miller, A. D., and C. Buttimore.
1986.
Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production.
Mol. Cell. Biol.
6:2895-2902[Abstract/Free Full Text].
|
| 34.
|
Pinter, A.,
W. J. Honnen,
J. S. Tung,
P. V. O'Donnell, and U. Hammerling.
1982.
Structural domains of endogenous murine leukemia virus gp70s containing specific antigenic determinants defined by monoclonal antibodies.
Virology
116:499-516[Medline].
|
| 35.
|
Ragheb, J. A., and W. F. Anderson.
1994.
pH-independent murine leukemia virus ecotropic envelope-mediated cell fusion: implications for the role of the R peptide and p12E TM in viral entry.
J. Virol.
68:3220-3231[Abstract/Free Full Text].
|
| 36.
|
Rein, A.,
J. Mirro,
J. G. Haynes,
S. M. Ernst, and K. Nagashima.
1994.
Function of the cytoplasmic domain of a retroviral transmembrane protein: p15E-p2E cleavage activates the membrane fusion capability of the murine leukemia virus Env protein.
J. Virol.
68:1773-1781[Abstract/Free Full Text].
|
| 37.
|
Rein, A.,
C. Yang,
J. A. Haynes,
J. Mirro, and R. W. Compans.
1998.
Evidence for cooperation between murine leukemia virus Env molecules in mixed oligomers.
J. Virol.
72:3432-3435[Abstract/Free Full Text].
|
| 38.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 39.
|
Skov, H., and K. B. Andersen.
1993.
Mutational analysis of Moloney murine leukemia virus surface protein gp70.
J. Gen. Virol.
74:707-714[Abstract/Free Full Text].
|
| 40.
|
Thomas, A., and M. J. Roth.
1995.
Analysis of cysteine mutations on the transmembrane protein of Moloney murine leukemia virus.
Virology
211:285-289.
|
| 41.
|
Turner, D. L., and C. L. Cepko.
1987.
A common progenitor for neuron and glia persists in rat retina late in development.
Nature
328:131-136[Medline].
|
| 42.
|
White, J. M.
1992.
Membrane fusion.
Science
258:917-924[Abstract/Free Full Text].
|
| 43.
|
White, J. M.
1990.
Viral and cellular membrane fusion proteins.
Annu. Rev. Physiol.
52:675-697[Medline].
|
| 44.
|
Yu, H.,
N. Soong, and W. F. Anderson.
1995.
Binding kinetics of ecotropic (Moloney) murine leukemia retrovirus with NIH 3T3 cells.
J. Virol.
69:6557-6562[Abstract].
|
| 45.
| Zavorotinskaya, T. Unpublished results.
|
| 46.
|
Zhao, Y.,
S. Lee, and W. F. Anderson.
1997.
Functional interactions between monomers of the retroviral envelope protein complex.
J. Virol.
71:6967-6972[Abstract].
|
Journal of Virology, July 1999, p. 5621-5629, Vol. 73, No. 7
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Argaw, T., Figueroa, M., Salomon, D. R., Wilson, C. A.
(2008). Identification of Residues outside of the Receptor Binding Domain That Influence the Infectivity and Tropism of Porcine Endogenous Retrovirus. J. Virol.
82: 7483-7491
[Abstract]
[Full Text]
-
Kumar, P., Nachagari, D., Fields, C., Franks, J., Albritton, L. M.
(2007). Host Cell Cathepsins Potentiate Moloney Murine Leukemia Virus Infection. J. Virol.
81: 10506-10514
[Abstract]
[Full Text]
-
Song, C., Micoli, K., Bauerova, H., Pichova, I., Hunter, E.
(2005). Amino Acid Residues in the Cytoplasmic Domain of the Mason-Pfizer Monkey Virus Glycoprotein Critical for Its Incorporation into Virions. J. Virol.
79: 11559-11568
[Abstract]
[Full Text]
-
Muster, T., Waltenberger, A., Grassauer, A., Hirschl, S., Caucig, P., Romirer, I., Fodinger, D., Seppele, H., Schanab, O., Magin-Lachmann, C., Lower, R., Jansen, B., Pehamberger, H., Wolff, K.
(2003). An Endogenous Retrovirus Derived from Human Melanoma Cells. Cancer Res.
63: 8735-8741
[Abstract]
[Full Text]
-
Ito, H., Watanabe, S., Takada, A., Kawaoka, Y.
(2001). Ebola Virus Glycoprotein: Proteolytic Processing, Acylation, Cell Tropism, and Detection of Neutralizing Antibodies. J. Virol.
75: 1576-1580
[Abstract]
[Full Text]
-
Bachrach, E., Marin, M., Pelegrin, M., Karavanas, G., Piechaczyk, M.
(2000). Efficient Cell Infection by Moloney Murine Leukemia Virus-Derived Particles Requires Minimal Amounts of Envelope Glycoprotein. J. Virol.
74: 8480-8486
[Abstract]
[Full Text]
-
Szurek, P. F., Brooks, B. R.
(2000). Synthesis of Virus-Specific High-Mobility DNA after Temperature Upshift of SC-1 Cells Chronically Infected with Moloney Murine Leukemia Virus Mutant ts1. J. Virol.
74: 7055-7063
[Abstract]
[Full Text]
-
Blond, J.-L., Lavillette, D., Cheynet, V., Bouton, O., Oriol, G., Chapel-Fernandes, S., Mandrand, B., Mallet, F., Cosset, F.-L.
(2000). An Envelope Glycoprotein of the Human Endogenous Retrovirus HERV-W Is Expressed in the Human Placenta and Fuses Cells Expressing the Type D Mammalian Retrovirus Receptor. J. Virol.
74: 3321-3329
[Abstract]
[Full Text]
-
O'Reilly, L., Roth, M. J.
(2000). Second-Site Changes Affect Viability of Amphotropic/Ecotropic Chimeric Enveloped Murine Leukemia Viruses. J. Virol.
74: 899-913
[Abstract]
[Full Text]
-
Zavorotinskaya, T., Albritton, L. M.
(1999). A Hydrophobic Patch in Ecotropic Murine Leukemia Virus Envelope Protein Is the Putative Binding Site for a Critical Tyrosine Residue on the Cellular Receptor. J. Virol.
73: 10164-10172
[Abstract]
[Full Text]